Estimation of contribution of CYP2D6 to tipepidine metabolism in humans and prolongation of the half-life of tipepidine by combination use with a CYP2D6 inhibitor in chimeric mice with humanised liver

Abstract

1. Recently, it has been reported that tipepidine has various central pharmacological effects and can be expected to be safely repositioned as a treatment for psychiatric disorders. Since tipepidine has a very short half-life and requires three doses per day, the development of a once-daily medication would be highly beneficial to improve adherence and quality of life in patients with chronic psychiatric disorders. The aim of this study was to identify the enzymes involved in tipepidine metabolism and to verify that combination use with an enzyme inhibitor prolongs the half-life of tipepidine.

2. Metabolism studies using recombinant human cytochrome P450 (P450, CYP) isoforms and inhibition studies using various selective P450 inhibitors and human liver microsomes revealed that CYP2D6 is the main enzyme catalysing tipepidine metabolism, with a metabolic contribution ratio of 85.4%.

3. Furthermore, a pharmacokinetic study using chimeric mice with humanised liver showed that oral coadministration of a CYP2D6 inhibitor, quinidine, increased the C_max, AUC_0-t, and t_1/2 of tipepidine by 1.5-, 3.2-, and 3.0-fold, respectively.

4. These results indicated that coadministration of a CYP2D6 inhibitor is effective in increasing plasma exposure and prolonging the half-life of tipepidine and is useful for repositioning tipepidine as a treatment for psychiatric disorders.

Keywords:

• Tipepidine
• Drug repositioning
• CYP2D6
• Drug interaction
• Chimeric mice with humanised liver
• Pharmacokinetics

Disclosure statement

The authors declare no conflict of interest. Shun Hayashi, Hiroko Kawaguchi, Takao Watanabe, Izuru Miyawaki are employees of Sumitomo Pharma Co., Ltd.

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.